Duvyzat (givinostat) Coverage for Duchenne Muscular Dystrophy
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Duvyzat oral suspension in patients with Duchenne muscular dystrophy. It applies to providers requesting initial or continued therapy for eligible patients.
The initial-authorization criteria were updated to address patients who previously received gene therapy for Duchenne muscular dystrophy.
The reauthorization criterion addressing previous gene therapy treatment for Duchenne muscular dystrophy was removed.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.